Lingkang Pharmaceutical released its 2026 interim report, with net profit attributable to the parent company of 21.11 million yuan, an increase of 56.85 million yuan compared with the same period last year, achieving a turnaround from loss to profit. The company's total operating revenue was 257 million yuan, up 50.03 percent year on year, marking a third consecutive year of growth. Net cash outflow from operating activities was 14.20 million yuan, narrowing by 24.76 million yuan compared with the same period last year. The company's latest gross margin was 41.31 percent, up 23.43 percentage points year on year; the latest return on equity was 3.29 percent, up 8.16 percentage points year on year.
Lionco Pharm Grp Co LtdCompany swung to profit with net profit of 21.11 million yuan, revenue up 50.03%.